De Novo device
Hemospray Endoscopic Hemostat (HEMO-[X])
Wilson-Cook Medical, Inc. · Hemostatic Device For Endoscopic Gastrointestinal Use (QAU, Class II) · First FDA decision May 7, 2018, newest Jun 2, 2026Gastrointestinal bleeding
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
12
Naming "Hemospray"
MAUDE reports
1,113
Brand "Hemospray", since 2015
PubMed studies
144
Mentioning "Hemospray"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hemospray Endoscopic Hemostat (HEMO-[X])
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K253302 · Decided Jun 2, 2026 · 246 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
K200972 · Decided Jun 10, 2020 · 58 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
- Hemospray Endoscopic HemostatNew device typeDe Novo
DEN170015 · Decided May 7, 2018 · 424 days after receipt
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hemospray", any status and sponsor, newest update first.
- HemosprayTM for Gastrointestinal Bleeding From CancerPivotal-lookingStatus unknown
King Chulalongkorn Memorial HospitalAcademic, hospital or other
NCT03855904 · 112 participants · Start Jun 1, 2019 · Primary completion Aug 31, 2022
Device: TC-325 · For: Gastrointestinal Bleeding From Malignancy
Sites: Bangkok, Thailand
Instituto do Cancer do Estado de São PauloAcademic, hospital or other
NCT02820077 · 62 participants · Start Aug 6, 2016 · Primary completion Jan 24, 2020
Device: Hemospray (Endoscopic treatment with hemostatic powder) · For: Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms
- To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal CausesPivotal-lookingCompleted
Chinese University of Hong KongAcademic, hospital or other
NCT02534571 · 224 participants · Start Sep 7, 2015 · Primary completion Jan 14, 2019
Device: Endoscopic Application of a Hemostatic Powder TC-325; Hemo-clipping and 1 more · For: Acute Upper Gastrointestinal Bleeding
Sites: Hong Kong, China
Changi General HospitalAcademic, hospital or other
NCT02088385 · 20 participants · Start Nov 2013 · Primary completion Mar 2015
Device: Hemospray; Combined Conventional Technique · For: Bleeding Peptic Ulcers
Sites: Singapore, Singapore
King Chulalongkorn Memorial HospitalAcademic, hospital or other
NCT03066700 · 90 participants · Start Mar 1, 2017 · Primary completion Jun 1, 2017
Device: Hemostatic powder · For: Death
Sites: Bangkok, Thailand
Hospital Universitario Ramon y CajalAcademic, hospital or other
NCT03611504 · 261 participants · Start Jul 1, 2018 · Primary completion Dec 30, 2018
Device: Hemospray® · For: Gastrointestinal Hemorrhage; Ulcer Hemorrhage; Tumor Bleeding
Sites: Madrid, Spain
Cook Group IncorporatedNot on our public-company list
NCT01306864 · 67 participants · Start Dec 2011 · Primary completion Apr 30, 2017
Device: Hemospray Kit · For: Bleeding Peptic Ulcers
Sites: Edmonton, Canada; Vancouver, Canada; Winnipeg, Canada · 12 sites in all
- RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal BleedingPivotal-lookingCompleted
Theodor Bilharz Research InstituteAcademic, hospital or other
NCT03061604 · 105 participants · Start Nov 2014 · Primary completion Nov 2017
Device: Hemospray · For: Variceal Hemorrhage
Sites: Brussels, Belgium; Giza, Egypt
Cook Group IncorporatedNot on our public-company list
NCT02099435 · 50 participants · Start Jan 2015 · Primary completion Nov 6, 2016
Device: Hemospray · For: Colonic Diverticula; Angiodysplasia; Colonic Polyp
Sites: Edmonton, Canada; Kingston, Canada; Montreal, Canada · 4 sites in all
University of Sao Paulo General HospitalAcademic, hospital or other
NCT02537353 · 40 participants (planned) · Start Sep 2015 · Primary completion Jul 2017
Device: Metal clips · For: Upper Gastrointestinal Bleeding
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hemospray", and for the whole product code for context.
This brand
1,113 reports: 929 malfunction, 175 injury, 9 death
Whole product code QAU
1,141 reports: 957 malfunction, 175 injury, 9 death
Newest reports for this brand
- Hemospray Endoscopic HemostatMalfunction
1037905-2026-00717 · Received Oct 29, 2026 · Event dated Oct 1, 2026
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Activation Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
1037905-2026-00712 · Received Oct 28, 2026
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Entrapment of Device
Patient problem as coded: Device Embedded In Tissue or Plaque
- Hemospray Endoscopic HemostatMalfunction
1037905-2026-00699 · Received Oct 27, 2026 · Event dated Sep 24, 2026
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Premature Activation
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Hemospray Endoscopic HemostatMalfunction
1037905-2026-00700 · Received Oct 27, 2026 · Event dated Jun 21, 2026
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Improper or Incorrect Procedure or Method; Activation Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Hemospray Endoscopic HemostatMalfunction
1037905-2026-00706 · Received Oct 27, 2026 · Event dated Aug 27, 2026
Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Device problem as coded: Activation Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-3177-2026 · Started Aug 20, 2026 · Posted by FDA Sep 16, 2026
Reason given: Due to issue with endoscope adherence and inability to spray powder. Firm will provide an updated Instruction for Use (IFU).
Cause as FDA categorized it: Labeling design · Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Z-0036-2025 · Started Aug 29, 2024 · Posted by FDA Oct 16, 2024
Reason given: Specific lots of product have been manufactured with nonconforming raw materials.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
- Hemospray Endoscopic Hemostat: Reference Part Numbers: a) HEMO-7, REF G56572; b) HEMO-7-EU, REF G24663;Open, Classified
Z-1978-2023 · Started May 22, 2023 · Posted by FDA Jun 21, 2023
Reason given: There are potential risks of the Hemospray powder adhering to the distal end of the endoscope, which can result in adhesion of the endoscope to tissue and consequent difficulty or inability to maneuver/remove the endoscope.
Cause as FDA categorized it: Under Investigation by firm · Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
- Hemospray Endoscopic Hemostat: Reference Part Numbers: a) HEMO-10, REF G21049; b) HEMO-10-EU, REF G21346Open, Classified
Z-1979-2023 · Started May 22, 2023 · Posted by FDA Jun 21, 2023
Reason given: There are potential risks of the Hemospray powder adhering to the distal end of the endoscope, which can result in adhesion of the endoscope to tissue and consequent difficulty or inability to maneuver/remove the endoscope.
Cause as FDA categorized it: Under Investigation by firm · Device type: Hemostatic Device For Endoscopic Gastrointestinal Use (QAU)
Published research
The most relevant PubMed records for "Hemospray"[tiab]. The summary above synthesizes these.
- Hemospray Versus Conventional Therapy for Non-variceal Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Shah MP, Saleem S, Attar B, et al. · Cureus · 2024Review
- Gastrointestinal Bleeding in Children: Current Management, Controversies, and Advances.
Novak I, Bass LM · Gastrointest Endosc Clin N Am · 2023Review
- Hemospray for treatment of acute bleeding due to upper gastrointestinal tumours.
Arena M, Masci E, Eusebi LH, et al. · Dig Liver Dis · 2017Multicenter Study
- Hemospray treatment is effective for lower gastrointestinal bleeding.
Holster IL, Brullet E, Kuipers EJ, et al. · Endoscopy · 2014
- Is hemospray the ultimate answer to malignant GI bleeding?
Chan SM, Lau JYW · Gastrointest Endosc · 2020Editorial, Comment
- The efficacy of Hemospray in managing bleeding related to gastrointestinal tumors: systematic review and meta-analysis.
Abosheaishaa H, Abdallfatah A, Ahmed OT, et al. · Eur J Gastroenterol Hepatol · 2024Systematic Review, Meta-Analysis
- Efficacy of Hemospray in Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Mutneja H, Bhurwal A, Go A, et al. · J Gastrointestin Liver Dis · 2020Meta-Analysis, Systematic Review
- Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy.
Hussein M, Alzoubaidi D, Serna A, et al. · United European Gastroenterol J · 2020Multicenter Study, Observational Study
- Effects of a hemostatic powder hemospray on coagulation and clot formation.
Holster IL, van Beusekom HM, Kuipers EJ, et al. · Endoscopy · 2015Evaluation Study, Research Support, Non-U.S. Gov't
- The Efficacy and Safety of Hemospray for the Management of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Ofosu A, Ramai D, John F, et al. · J Clin Gastroenterol · 2021Meta-Analysis, Systematic Review
- Hemospray hemostasis in bleeding diffusely ulcerated esophagus.
Tang SJ, Hosseini-Carroll P, Vesa TS · VideoGIE · 2019
- Advancements in hemostatic strategies for managing upper gastrointestinal bleeding: A comprehensive review.
Lee AY, Cho JY · World J Gastroenterol · 2024Editorial
Other devices of this type
Also filed under product code QAU.
- PuraStat3-D Matrix Europe SAS · 510(k) 2026
- NexpowderNextbiomedical Co., Ltd. · 510(k) 2024
- PuraStat GI3-D Matrix, Inc. · 510(k) 2026
- Resolv Endoscopic Hemostat SystemHemostasis, LLC · 510(k) 2024
- PuraStat3-D Matrix, Inc. · 510(k) 2023
- PuraStat-GI3-D Matrix, Inc. · 510(k) 2021
- EndoClotEndoclot Plus Co., Ltd. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.